Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
08/2010
08/04/2010CN101791295A Compound monoammonium glycyrrhizinate S pharmaceutical composition and method for preparing frozen powder injection
08/04/2010CN101791294A Novel spherical pellet preparation and process thereof
08/04/2010CN101791293A Allicin liposome for resisting microbe, protozoan and tumor and preparation method thereof
08/04/2010CN101791290A Tetra-acetylated puerarin self-micro emulsifying medicament delivery system and preparation method thereof
08/04/2010CN101791289A Ganciclovir resin slow-release suspension and preparation method thereof
08/04/2010CN101791288A Stable lenalidomide oral solid preparation
08/04/2010CN101791287A Solid oral drug composite containing aripiprazole microcrystalline
08/04/2010CN101647775B Micronomicin sulfate eye drop and preparation method thereof
08/04/2010CN101317823B Implantation type antineoplastic drug of 10-hydroxycamptothecin dual-sustained-release particle formulation and preparation method thereof
08/04/2010CN101269013B Method for preparing polymer microsphere
08/03/2010US7767717 Including keloid and hypertrophic scars; use in hydroalcoholic solutions and hydroalcoholic gels
08/03/2010US7767698 A pharmaceutical liquid comprising nicotine, a buffer or pH controller; spraying an aerosol into the mouth for deliverying into the lungs, for treating tobacco addiction; new pharmaceutical formulation
08/03/2010US7767656 Blends of temperature sensitive and anionic polymers for drug delivery
08/03/2010US7767649 Gamma aminobutyric acid antagonist; naphthylalanine; antiepileptic agents; antidepressants; anxiolytic agents; psychological disorders; neurodegenerative disorders; analgesics; drug withdrawal
08/03/2010US7767648 Prostate specific antigen; immobilization; antiproliferative agents; drug delivery; contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA); useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs
08/03/2010US7767644 contains at least four amino acids selected from leucine, isoleucine, threonine, glutamic acid, aspartic acid and phenylalanine, and in which the addition of preservatives, urea or human serum albumine can be foregone; storage stability
08/03/2010US7767456 Non-viral gene delivery system
08/03/2010US7767429 use to treat glycosaminoglycan associated pathologies such as eye disorders or tumors; sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes; transgenic animals; dosage forms; HYLENEX RECOMBINANT tradename
08/03/2010US7767403 Binding monoclonal, humanized, or fragment of antibody to human cell that expresses a protein; cancer
08/03/2010US7767300 Hydroxyapatite calcium phosphates, their method of preparation and their applications
08/03/2010US7767239 nutritional fluid mixture comprising water, whey protein, electrolytes, vitamin C and aspartame with a low concentration of sugar; topical moisturizers
08/03/2010US7767235 Grape extract, dietary supplement thereof, and processes therefor
08/03/2010US7767232 Control of nitric oxide bioactivity by perfluorocarbons
08/03/2010US7767230 Organic compounds
08/03/2010US7767229 Use of poly diallyamine polymers
08/03/2010US7767227 Galenical form for oral administration with prolonged release of molsidomine
08/03/2010US7767223 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
08/03/2010US7767220 Implantable or insertable medical articles having covalently modified, biocompatible surfaces
08/03/2010US7767198 Aerosolizing dry powder of interleukin-4 receptor with carbohydrage, lipid, buffer, peptide, protein, Group II metal, or oligopeptide excipient; small aerodynamic particle size; dispersion into gas stream to make inhalant; high dispersibilities
08/03/2010CA2677670C Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
08/03/2010CA2661728C Generation of therapeutic microfoam
08/03/2010CA2612742C Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof
08/03/2010CA2502582C Pharmaceutical formulation of olanzapine
08/03/2010CA2476622C A transdermal patch
08/03/2010CA2455064C Transdermal therapeutic system based on polyacrylate contact adhesives without functional groups
08/03/2010CA2409828C Formulation based in heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
08/03/2010CA2407335C Process and device for producing liquid dosage formulations
08/03/2010CA2396524C System for stabilizing lacrimal fluid layer
08/03/2010CA2386325C Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses
08/03/2010CA2230748C Rapamycin formulations for oral administration
08/03/2010CA2227706C Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
08/03/2010CA2217462C Controlled release biodegradable micro- and nanospheres containing cyclosporin
07/2010
07/29/2010WO2010085651A1 In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
07/29/2010WO2010085123A2 Composition applicable to skin and capable of improving blood circulation and enlarging blood vessels
07/29/2010WO2010084637A1 Tablet for oral administration having excellent disintegrability and dissolvability
07/29/2010WO2010084601A1 Powdery fat-containing soft capsules to be masticated
07/29/2010WO2010084298A1 Stable vaccine compositions and methods of use
07/29/2010WO2010084292A1 Novel azapeptide or azapeptidomimetic compounds inhibiting bcrp and/or p-gp
07/29/2010WO2010084199A1 Drug delivery system for use in the treatment of vascular and vessel-related pathologies
07/29/2010WO2010084169A2 Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
07/29/2010WO2010084157A2 Multifunctional stealth nanoparticles for biomedical use
07/29/2010WO2010084129A1 Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids
07/29/2010WO2010084088A2 Starch nanoparticles for drug delivery systems
07/29/2010WO2010084060A1 Starch copolymers and nanoparticles thereof for drug delivery systems
07/29/2010WO2010083778A1 Lung targeting injectable pharmaceutical composition of liposome
07/29/2010WO2010083636A1 An eyedrops of the deproteinized calf blood extract
07/29/2010WO2010064252A3 Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents
07/29/2010WO2010063491A3 Transport-mediating colloidal pharmaceutical compounds
07/29/2010WO2010063483A9 Active ingredient-peptide construct for extracellular enrichment
07/29/2010WO2010056872A3 Antimicrobial compositions
07/29/2010WO2010054321A3 Methods of treating autoimmune disorders and/or inflammatory disorders
07/29/2010WO2010044597A3 Drug delivery device
07/29/2010WO2010042633A3 Naringenin complexes and methods of use thereof
07/29/2010WO2010041138A3 Complex between human insulin and an amphiphilic polymer, and use of said complex for preparing a quick human insulin formulation
07/29/2010WO2010023689A3 Microparticles
07/29/2010US20100190933 Multi-arm polymer prodrugs
07/29/2010US20100190928 Polymeric conjugates of doxorubicin with ph-regulated release of the drug and a method of preparing
07/29/2010US20100190873 Extract of the plant Ashwaganda (Withania Somnifera) consisting of the seeds of said plant dried and processed into a flour to be used as an ingredient to be incorporated in tablets and/or capsules for human consumption and/or to be available as a base for solvent extraction where said extaction(s) would be used for tablets and/or capsules for human consumption and/or human skin creams and/or lotions
07/29/2010US20100190872 Production of beta-glucans and mannans
07/29/2010US20100190870 Polymer comprising water soluble units and lcst units, and aqueous composition comprising same
07/29/2010US20100190869 Process for the isolation of dodecatrienal and its use as aroma substance
07/29/2010US20100190868 Photochromic and electrochromic compounds and synthesis and use thereof
07/29/2010US20100190738 Use of Aalkylphophocholines in Combination with Antitumor Medication for the Treatment of Benign and Melignant Oncoses in Humans and Mammals
07/29/2010US20100189815 Colon cleansing compositions and methods
07/29/2010US20100189809 Foamable Compositions Containing Alcohol
07/29/2010US20100189784 Use of Alkylphophocholine in Combination with Antitumor Medication for the Treatment of Benign and Malignant Oncoses in Humans and Mammals
07/29/2010US20100189763 Controlled release systems from polymer blends
07/29/2010US20100189718 Molecules with extended half-lives, compositions and uses thereof
07/29/2010US20100189686 Albumin Fusion Proteins
07/29/2010US20100189684 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY
07/29/2010US20100189667 Vesicles of high molecular weight silicone polyethers
07/29/2010US20100189649 Monoclonal antibodies to activated erbb family members and methods of use
07/29/2010US20100189643 Drug delivery with stimulus responsive biopolymers
07/29/2010US20100189596 Composite emulsifier, an emulsion prepared from it and the preparation method thereof
07/29/2010CA2750581A1 Pta089 protein
07/29/2010CA2750321A1 Stable vaccine compositions and methods of use
07/29/2010CA2749952A1 Novel azapeptide or azapeptidomimetic compounds inhibiting bcrp and/or p-gp
07/29/2010CA2748593A1 Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
07/28/2010EP2210956A2 Method to inhibit cell growth using oligonucleotides
07/28/2010EP2210622A1 Therapeutic agent for heart disease, which is intended to be used in cell transplantation therapy
07/28/2010EP2210616A1 Multifunctional stealth nanoparticles for biomedical use
07/28/2010EP2210608A1 Pharmaceutical composition containing human mesenchymal stem cell
07/28/2010EP2210599A1 Lidocaine tape preparation
07/28/2010EP2210595A1 Active coating of pharmaceutical dosage forms
07/28/2010EP2210593A2 Tablettable formulations of vitamin A and derivatives thereof
07/28/2010EP2210592A2 Stabilized Freeze-dried Formulation for Cephalosporin Derivatives
07/28/2010EP2210590A1 Drug delivery system for use in the treatment of vascular and vessel-related pathologies
07/28/2010EP2210584A1 Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
07/28/2010EP2210583A1 Gel sheet and cosmetic preparation in sheet form using the same
07/28/2010EP2209808A1 Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
1 ... 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 ... 1712